original contributions nature publishing group Heart failure (HF) constitutes a major public health problem because of a 20% lifetime risk of this condition for both men and women. 1 Despite improved survival after HF diagnosis (43% 5-year adjusted survival in 1979-1984 vs. 52% in 1996-2000, P < 0.001), 2 the mortality rate remains high; ~50% die within 5 years 2,3 and one in nine death certificates in the United States mention HF. 4 Hypertension, which affects ~1/3 of US adults ≥20 years of age, 4 is the most common risk factor for HF in the general population. 5, 6 In the Framingham Heart Study, hypertension carried the greatest population-attributable risk for HF of all risk factors, accounting for 39% of new HF cases in men and 59% in women. 7 In a review including ~200,000 hypertensive patients, HF development was more prevalent in older, black, diabetic and "very high" cardiovascular risk individuals. 8 Several trials have demonstrated that antihypertensive treatment is highly efficacious in reducing risk of HF. [9] [10] [11] [12] [13] [14] [15] Electrocardiographic left ventricular hypertrophy (ECG-LVH) is also an important independent risk factor for HF 7, [16] [17] [18] [19] [20] [21] [22] and studies have demonstrated that prevention 22 or regression 23 of ECG-LVH is associated with lower risk of incident HF in hypertensive patients. Isolated systolic hypertension (ISH) is the most common form of hypertension in the elderly and is associated with increased risk of cardiovascular morbidity and mortality as compared with systolic-diastolic hypertension or isolated diastolic hypertension. 24, 25 It is still unclear whether regression of ECG-LVH may prevent the development of HF in Background Hypertension and electrocardiographic left ventricular hypertrophy (EcG-LVH) are strong predictors of heart failure (HF). It is unclear whether regression of EcG-LVH during treatment predicts less newonset HF in patients with isolated systolic hypertension (ISH).
Background
Hypertension and electrocardiographic left ventricular hypertrophy (EcG-LVH) are strong predictors of heart failure (HF). It is unclear whether regression of EcG-LVH during treatment predicts less newonset HF in patients with isolated systolic hypertension (ISH).
Methods
A total of 9,027 patients with hypertension and EcG-LVH and without a history of HF were randomized to losartan-or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension study. Incident HF and the combined endpoint of HF and death were evaluated in 1,280 ISH patients and as compared with 7,747 patients with systolic-diastolic hypertension or isolated diastolic hypertension (non-ISH) during mean 4.8 ± 0.9 years follow-up. results New-onset HF and HF or death occurred in 57 (4.5%) and 179 (14.0%) ISH patients and 220 (2.8%) and 787 (10.2%) non-ISH patients. In cox regression analyses adjusting for treatment and HF risk factors, time-varying cornell product was associated with lower risk of newonset HF in ISH (adjusted hazard ratio (HR) 0.79, 95% confidence interval (cI) 0.67-0.94, P = 0.008, per 1,050 mm × ms (1 SD) lower cornell product) and in non-ISH (adjusted HR 0.67, 95% cI 0.61-0.72, P < 0.001, per SD lower cornell product). In parallel analyses, timevarying cornell product was associated with lower risk of new-onset HF or death in ISH and non-ISH (adjusted HR 0.83, 95% cI 0.75-0.93,
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Isolated Systolic Hypertension and Heart Failure older persons with ISH. Therefore, the aims of this pre-specified Losartan Intervention For Endpoint reduction in hypertension (LIFE) substudy were first, to investigate the effect of lower time-varying ECG-LVH determined by Cornell product on new-onset HF and the combined endpoint of HF or all-cause mortality in patients with ISH, and second, to compare patients with ISH vs. systolic-diastolic hypertension or isolated diastolic hypertension (non-ISH) in regard to incident HF and HF or all-cause mortality. The combined endpoint of HF or mortality was included in the analyses because this composite has often been used as primary or secondary endpoint in HF outcome studies because of high annual mortality. [26] [27] [28] [29] 
Methods
Study population. The LIFE study [30] [31] [32] enrolled 9,193 patients aged 55-80 years with essential hypertension (mean seated blood pressure (BP) 160-200 mm Hg systolic, 95-115 mm Hg diastolic, or both after placebo run-in) having ECG-LVH by Cornell voltage-duration product 33, 34 and/or Sokolow-Lyon voltage criteria 35 on a screening ECG in a prospective, doubleblind study comparing the occurrence of cardiovascular death, stroke and myocardial infarction between patients randomized to losartan-or atenolol-based therapy. Patients were followed for mean 4.8 ± 0.9 years and the treatment goal was ≤140/90 mm Hg. 30 ISH was defined as systolic BP ≥160 mm Hg and diastolic BP <90 mm Hg and was pre-specified as a subgroup of special interest in the original LIFE data analysis plan. Patients with isolated diastolic hypertension (systolic BP <140 mm Hg and diastolic BP ≥90 mm Hg) were few (n = 85) and they had pre-randomization diastolic BP ≥95 mm Hg in order to be included. In the present study, patients with a history of HF were excluded (n = 166) and therefore 1,280 ISH patients and 7,747 non-ISH patients were eligible for data analyses (Figure 1) . The trial protocol was approved by all ethics committees concerned; was in accordance with the Declaration of Helsinki and was overseen by an independent data and safety monitoring board. All participants gave written informed consent. The study data reside in a database with the authors.
Electrocardiography. ECGs were obtained at study baseline, at 6 months, and at yearly follow-up intervals until study termination or patient death. All ECGs were read at the core laboratory at Sahlgrenska University Hospital/Östra, Göteborg, Sweden, by experienced readers blinded to clinical information. QRS duration was measured to the nearest 4 ms and the QRS amplitudes to the nearest 0.5 mm (0.05 mV). The product of QRS duration × the Cornell voltage combination (R aVL + S V3 , with 8 mm added in women) 33, 34 was used with a threshold value of 2,440 mm × ms to identify LVH. The sex adjustment was reduced from 8 to 6 mm and Sokolow-Lyon voltage (S V1 + R V5/6 ) >38 mm was accepted for ECG eligibility in patients recruited after 30 April 1996. 31, 36 Endpoint determination. Hospitalization for new-onset or incident HF was a pre-specified secondary endpoint 30 and on the basis of the HF criteria from the Framingham Heart Study 37, 38 (Supplementary Figure S1 , online). In addition, because mortality was a competing event, a composite endpoint of all-cause mortality or new-onset HF (time to first event) was used in these analyses. Each case was verified by the Endpoint Committee, which was blinded to study
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Excluded from the analyses: patients with a history of heart failure (n = 40) performed by using mixed-effects linear models to account for the within-subject correlation. As previously described, 36 possible associations between Cornell product ECG-LVH during antihypertensive therapy and hospitalization for newonset HF were analyzed according to a pre-specified statistical analysis plan using Cox proportional hazard models 39 and on the basis of intention-to-treat principle. 32 In addition, parallel analyses were performed to assess possible associations between time-varying Cornell product and the combined endpoint of HF or all-cause mortality. In order to test the proportional hazards assumption, partial residuals were plotted against survival times. Univariate Cox regression analyses were performed to identify important predictors of HF in the ISH and non-ISH populations. Significant univariate predictors in the ISH population were then entered into multivariate analyses together with baseline and subsequent determinations of Cornell product entered as a time-varying covariate. Stepwise forward and backward regression was performed to identify the best fitted multivariate model for new-onset HF in the ISH population. This model was then used on both endpoints in both ISH and non-ISH populations in order to compare the results. Hazard ratios (HRs) for incident HF for time-varying Cornell product were computed per 1-SD-of-the-mean lower values of the Cornell product as the antilogarithm of the estimated coefficient multiplied by the SD. 40 The 95% confidence intervals (CI) of HRs were calculated from the estimated coefficients and their standard errors, 41 and Wald χ 2 statistics and probability values were calculated. In accordance with previous analyses, the Cornell product baseline SD (1,050 mm × ms) for the whole LIFE population was used in the calculations. 36 Interaction analyses were performed to test if the effects of regression of Cornell product on incident HF and the combined endpoint of HF and death were significantly different in ISH patients as compared with non-ISH patients. In separate Cox models with all 9,027 patients, Cornell product was entered as a time-varying covariate, and ISH status and the cross-product of ISH status and time-varying Cornell product were entered as standard covariates. The P value of these interaction crossproducts were used to determine if there were quantitative interactions, i.e., whether ISH increased or decreased the outcome effects of the regression in Cornell product. A two tailed P < 0.05 was required for statistical significance.
Figure 1 |

results characteristics and outcomes in patients with ish and non-ish
In 1,280 patients with ISH and ECG-LVH followed for mean 4.8 ± 0.9 years, new-onset HF occurred in 57 patients (4.5%) and new-onset HF or all-cause mortality occurred in 179 patients (14.0%). In 7,747 non-ISH patients new-onset HF occurred in 220 patients (2.8%) and new-onset HF or all-cause mortality in 787 patients (10.2%; Figure 1 ). Baseline demographic and clinical characteristics in patients with ISH and non-ISH are presented in Table 1 . These results were unaltered when adjusted for age and sex. In multivariate Cox regression analyses the independent effects of regression of time-varying Cornell product LVH for newonset HF and new-onset HF or mortality were examined after adjustment for treatment with losartan vs. atenolol, baseline Framingham risk score and urine albumin-creatinine ratio, history of atrial fibrillation and time-varying systolic BP in patients with ISH ( Table 4 ) and non-ISH ( Table 5 ). The effects of regression of time-varying Cornell product LVH were consistent for both endpoints in both populations when adjusted for time-varying diastolic BP, previous myocardial infarction, peripheral vascular disease, cerebrovascular disease, diabetes, estimated glomerular filtration rate or prior antihypertensive treatment in addition to treatment with losartan vs. atenolol, baseline Framingham risk score and urine albumin-creatinine ratio, history of atrial fibrillation and time-varying systolic BP. Tables 2 and 3) .
Possible interactions between time-varying Cornell product and ISH status were examined and there was a borderline significant interaction for HF (P = 0.050), but not for the combined endpoint of HF and all-cause mortality (P = 0.53): regression of Cornell product during antihypertensive treatment was associated with borderline greater decrease in risk for HF in patients with non-ISH (HR 0.67, 95% CI 0.61-0.72, P < 0.001) as compared with patients with ISH (HR 0.79, 95% CI 0.67-0.94, P = 0.008).
discussion
In 1,280 patients with ISH and ECG-LVH followed for a mean of 4.8 years, new-onset HF occurred in 4.5% and the combined endpoint of new-onset HF or all-cause mortality occurred in 14.0%. In 7,747 patients with systolic-diastolic hypertension or isolated diastolic hypertension and ECG-LVH, the incidences were 2.8% and 10.2%. Regression of time-varying Cornell product was associated with a 21% risk reduction for new-onset HF and a 17% risk reduction for new-onset HF or Data are presented as mean ± SD or number (%) of subjects. Differences in prevalences between groups were compared using χ 2 analyses and mean values of continuous variables were compared using independent-samples t-test. BP, blood pressure; GFR, glomerular filtration rate; HDL, high-density lipoprotein; ISH, isolated systolic hypertension; non-ISH, systolic-diastolic hypertension/isolated diastolic hypertension; UACR, urine albumin-creatinine ratio. a Log UACR was used in the t-test because of skewed distribution of UACR. *P < 0.05 as compared with ISH patients.
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Isolated Systolic Hypertension and Heart Failure all-cause mortality per 1,050 mm x ms (SD) in patients with ISH, independent of treatment with losartan vs. atenolol, baseline Framingham risk score and urine albumin-creatinine ratio, history of atrial fibrillation and time-varying systolic BP. In parallel analyses, regression of time-varying Cornell product was associated with a 33% risk reduction for new-onset HF and an 18% risk reduction for new-onset HF or all-cause mortality per SD in patients with non-ISH. There was a borderline significant interaction (P = 0.050) between ISH status and time-varying Cornell product in regard to new-onset HF (21% risk reduction per SD in ISH vs. 33% risk reduction per SD in non-ISH). However, in regard to the combined endpoint of HF or all-cause mortality, regression of time-varying Cornell product was independently associated with similar significant risk reductions in both subsets of hypertensives. The results of the mixed-effects models (Figure 2a,b) complement these findings. Sex and smoking were not univariate predictors of HF in ISH, perhaps because of low statistical power. In a study evaluating the prognostic significance of serial ECG voltage in 4,159 patients with ISH enrolled in the SystEur trial, Fagard et al. 21 found a strong association between baseline ECG LV mass defined as the sum of three voltages To our knowledge this is the first study to demonstrate that regression of ECG-LVH during antihypertensive treatment is associated with lower risk of HF in ISH patients, and the finding is restricted to regression of LVH by the Cornell product criteria. Our findings do not exclude that regression of LVH by voltage criteria (e.g., Sokolow-Lyon) is important since the majority of our participants were recruited by having LVH with Cornell product criteria. 31 The result showing no significant association between regression of Sokolow-Lyon voltage and lower risk of HF may be due to lack of power. Furthermore, the interaction analyses showed borderline significance (P = 0.050) for stronger association between regression of Cornell product with less HF in non-ISH than in ISH patients. Taking the Syst-Eur voltage data, 21 and our Sokolow-Lyon findings in the present study together, this finding may overall rank ISH patients somewhat weaker than non-ISH patients in using ECG-LVH regression to predict incident HF. However, for the combined endpoint of HF and mortality, the two subsets of hypertensive patients came out similarly which again supports the use of Cornell product in ISH patients.
Interestingly, incident HF may behave differently in relation to regression of ECG-LVH in ISH and non-ISH patients as compared with the primary cardiovascular endpoint in LIFE namely the composite of myocardial infarction, stroke and cardiovascular mortality. 42 There was a significant interaction between lower time-varying Sokolow-Lyon voltage and lower risk of the composite endpoint in ISH vs. non-ISH patients (P = 0.048); ISH patients had an increased outcome effect of regression of time-varying Sokolow-Lyon voltage as compared with non-ISH patients. 42 Overall, these data support the view that both ISH and non-ISH patients should be carefully monitored for regression of ECG-LVH by both Cornell product and Sokolow-Lyon criteria during the treatment of hypertension.
We assessed the composite endpoint of incident HF or mortality for several reasons. First, death is a competing risk and patients that die do not have the opportunity to get the endpoint HF. When comparing ISH to non-ISH it is essential to use the composite because of significant difference in mortality. Second, both incident HF and mortality were pre-specified endpoints and combining them would increase the number of endpoints in the study and the statistical power. Third, hypertension with LVH may be the most important source of HF with subsequent high mortality. [5] [6] [7] [9] [10] [11] [12] [13] [16] [17] [18] [19] [20] [21] [22] Fourth, this composite endpoint has been the primary or secondary endpoint in many outcome trials in patients with HF [26] [27] [28] [29] and this approach allows a brief comparison of incidences which ranged from 11 to 40% in the HF trials 26, 28, 29 as compared with 14% in the LIFE ISH population and 11% in the total LIFE population, taking into account that patients in the HF trials had more severe heart disease at baseline.
To summarize, we investigated incident HF and the combined endpoint of HF or death in 1,280 patients with ISH and as compared with 7,747 patients with non-ISH, all with ECG-LVH at baseline, during a mean of 4.8 ± 0.9 years of antihypertensive treatment. Regression of LVH measured as timevarying Cornell product was associated with similar reductions in risk of new-onset HF and the combined endpoint of HF or death in ISH and non-ISH patients.
limitations
This is a LIFE substudy in patients with ISH, however, ISH patients were selected a priori as being of special interest. Patients were predominantly white. They had hypertension and ECG-LVH, and increased risk of cardiovascular events as compared with hypertensives without LVH. The phenomenon of regression to the mean 43 may impact the current findings, in regard to the use of Cornell product and Sokolow-Lyon volt- original contributions Isolated Systolic Hypertension and Heart Failure age above threshold levels to select patients for the LIFE study. Separate screening and baseline ECGs were used in attempt to minimize this problem. 30, 31, 36 Because of this selection process and the intrinsic variability of ECG measurements, [43] [44] [45] [46] it is likely that both the degree of ECG-LVH at baseline and the subsequent decrease in LVH during therapy were overestimated in some patients. Despite these limitations, lower Cornell product was associated with lower risk of HF, which would actually bias against our findings, because these overestimations as a result of statistical fluctuations would lead to a more conservative estimate of the impact of ECG-LVH on outcome. The use of hospitalization for HF to define HF probably underestimates the true incidence of HF which may attenuate the precision of the results. HF was a pre-specified secondary endpoint, however, the LIFE study was designed and had statistical power for the primary composite endpoint. Therefore, the hazard ratios for HF and HF or all-cause mortality require careful interpretation. 
